Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up-Reference-Cited by-同舟云学术

Ipilimumab in a real‐world population: A prospective Phase IV trial with long‐term follow‐up

Published:2021-09-09 Issue:1 Volume:150 Page:100-111
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Aamdal Elin¹²³^ORCID,Jacobsen Kari D.¹,Straume Oddbjørn⁴⁵,Kersten Christian⁶,Herlofsen Oluf⁷,Karlsen Jarle⁸,Hussain Israr⁹,Amundsen Anita¹⁰,Dalhaug Astrid¹¹,Nyakas Marta¹²,Schuster Cornelia⁴⁵,Hagene Kirsten T.¹,Holmsen Kjersti¹,Russnes Hege G.¹²¹³,Skovlund Eva¹⁴,Kaasa Stein¹²,Aamdal Steinar¹²,Kyte Jon A.¹,Guren Tormod K.¹

Affiliation:

1. Department of Oncology Oslo University Hospital Oslo Norway

2. Institute of Clinical Medicine, Faculty of Medicine University of Oslo Oslo Norway

3. Department of Oncology Akershus University Hospital Lørenskog Norway

4. Department of Oncology and Medical Physics Haukeland University Hospital Bergen Norway

5. Centre for Cancer Biomarkers, Department of Clinical Science University of Bergen Bergen Norway

6. Research Unit Sørlandet Hospital Kristiansand Norway

7. Department of Oncology Ålesund Hospital Ålesund Norway

8. The Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital Trondheim Norway

9. Department of Hematology and Oncology Stavanger University Hospital Stavanger Norway

10. Department of Oncology University Hospital of North Norway Tromsø Norway

11. Department of Oncology and Palliative Medicine Nordland Hospital Norway

12. Department of Pathology Oslo University Hospital Oslo Norway

13. Department of Cancer Genetics Institute for Cancer Research, Oslo University Hospital Oslo Norway

14. Department of Public Health and Nursing Norwegian University of Science and Technology, NTNU Trondheim Norway

Funder

Kreftforeningen

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33768

Reference49 articles.

1. Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

3. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

4. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

5. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis;Cancers;2024-01-13

2. Assessment of Variables Related to the Risk of Severe Adverse Events in Cutaneous Melanoma Patients Treated with Immune Checkpoint Inhibitors;Cancers;2024-01-05

3. Immune Checkpoint Inhibitor-Induced Liver Injury;Seminars in Liver Disease;2023-11

4. Treatment response and recurrence of conjunctival melanoma with orbital invasion treated with immune checkpoint inhibitors: case report and literature review;Orbit;2023-04-13

5. Therapeutic cancer vaccination against telomerase: clinical developments in melanoma;Current Opinion in Oncology;2023-01-16